Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
Returns on capital
Replimune Group, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.5%
avg -11.9%
ROIC
-53.1%
avg -33.4%
ROA
-44.9%
avg -29.2%
Analysis
ROA is currently the strongest return metric at -44.9% versus its period average of -29.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sushil Patel | Chief Executive Officer & Director | USD 1.02M | 55 | 708.15K | 0.86% |
Philip Astley-Sparke | Executive Chairman | USD 960.52K | 55 | 1.36M | 1.65% |
Konstantinos Xynos | Chief Medical Officer | USD 748.53K | 60 | 224.22K | 0.27% |
Emily Luisa Hill | Chief Financial Officer | USD 728.32K | 46 | 215.85K | 0.26% |
Michelle DiNapoli | Chief Commercial Officer | USD 594.58K | — | — | — |
Andrew Schwendenman | Chief Accounting Officer & Treasurer | — | 50 | 99.42K | 0.12% |
Camilo Garcia | Chief Human Resource Officer | — | — | — | — |
Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | — | — | — | — |
Shawn Glidden | Chief Legal Officer | — | — | — | — |
Arleen Goldenberg | Head of Investor Relations | — | — | — | — |
Kari Jeschke | Senior Vice President of Regulatory Affairs | — | — | — | — |
Nina Aragam | Chief Operations Officer | — | — | — | — |
Carolyn Trott | Senior Vice President of Quality Assurance | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$273.63
Sells
17
$2.34M
Net Transaction Value
−$2.34M
Net selling
Most Active
Hill Emily Luisa
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 9, 26Nov 9, 2026 | SLATTERY JOSEPH P Direct | Sell | $113.4K$113,360.00 |
| Nov 2, 26Nov 2, 2026 | Dhingra Kapil Direct | Sell | $408.5K$408,500.00 |
| Aug 17, 26Aug 17, 2026 | Hill Emily Luisa Direct | Sell | $132.2K$132,175.68 |
| Aug 11, 26Aug 11, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $261$260.99 |
| Aug 11, 26Aug 11, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $12.6$12.64 |
| Aug 10, 26Aug 10, 2026 | Patel Sushil Direct | Sell | $510.3K$510,252.77 |
| Aug 10, 26Aug 10, 2026 | Hill Emily Luisa Direct | Sell | $148.5K$148,480.56 |
| Aug 10, 26Aug 10, 2026 | Xynos Konstantinos Direct | Sell | $148.5K$148,467.59 |
| Aug 10, 26Aug 10, 2026 | Schwendenman Andrew Direct | Sell | $99K$98,987.04 |
| Jun 1, 26Jun 1, 2026 | Sarchi Christopher Direct | Sell | $110.9K$110,880.00 |
1–10 of 19
Summary
Insiders reported 2 buys worth $273.63 and 17 sells worth $2.34M over the last 12 months. That adds up to net selling of $2.34M. Hill Emily Luisa was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Replimune Group, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about REPL's management, answered from reported figures.
Who manages REPL?
Replimune Group, Inc. (REPL) lists 13 active executives. The top listed executive is Konstantinos Xynos, Chief Medical Officer.
Are REPL insiders buying or selling?
Recent insider activity shows net buying of $32.31M.
Continue the stock analysis
Jump to another research area for this company.